SELLAS Life Sciences Group, Inc. SLS Cash Flow

Sellas life sciences group, inc. (SLS)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12
Cash flows from operating activities:
Net loss
-18,898	-19,292	-25,196	-21,284	-24,212	-27,670	-23,132	-27,297	-27,148	-23,754	0	0	0	-	-	-	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net loss
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	0	0	0	-	0	0	0
Adjustment to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense
-	-	-	-	-	-	-	-	-	-	-	-	-	3	-102	-9	15	107	50	-194	-48	86	458	706	516	286	170	46	9	49	0	0	0
Non-cash accretion of debt issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash interest expense
-	-	-	-	-	134	-124	-143	20	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss on disposal of equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Deferred income taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,052	-1,115	-2,273	-3,814	-1,052	0	0	0
Non-cash rent expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Accretion and receipt of bond discount
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Non-cash stock-based compensation
533	573	537	559	558	395	-323	807	2,254	3,169	2,300	1,585	635	354	2,427	2,450	2,216	1,931	2,122	2,289	3,414	4,666	4,841	4,828	3,566	2,307	1,670	1,388	1,331	1,394	0	0	0
Change in fair value of warrants potentially settleable in cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Fair value of common stock issued in exchange for services
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Fair value of common stock issued in connection with litigation settlements
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Change in fair value of common stock warrants
976	1,136	1,070	3,356	3,616	5,302	5,340	3,099	1,881	0	0	0	0	-	16,315	14,796	-3,862	1,161	2,400	7,002	7,915	16,556	-23,692	-32,041	-29,206	-44,001	-6,011	-4,664	-34,048	-10,775	0	0	0
Fair value of common stock issued in exchange for licensing rights
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Change in fair value of contingent consideration
-337	-586	483	349	-8	-3,032	-4,025	-3,863	-3,411	0	0	0	0	-	5,622	6,074	660	509	298	588	15	170	-426	-1,195	-649	-926	-910	-1,209	-3,657	-2,370	0	0	0
Loss on settlement of liability-classified warrants
-	-	-	-	-	727	727	727	685	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Changes in operating assets and liabilities:
Accounts receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	0	0	0	-	-	-	-
Inventories
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	0	0	0	-	-	-	-
Prepaid expenses and other assets
1,124	76	-270	-501	-532	-212	468	534	663	-73	855	615	781	477	-162	360	-143	245	756	483	1,122	1,078	-21	53	-186	-437	-334	-376	85	396	0	0	0
Litigation settlement insurance recovery
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	1,700	21,700	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Litigation settlement payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,000	4,100	4,000	24,000	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable
-2,174	12	-3,710	-8,607	-6,813	-7,936	3,536	9,077	4,541	8,366	0	0	0	-	-344	212	-892	-289	-723	-222	1,090	-21	71	-809	-1,302	-69	-320	386	362	641	0	0	0
Due to former parent
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Accrued expenses and other current liabilities
81	-1,048	-3,179	-2,819	-4,891	-2,282	-2,277	-2,875	2,661	-2,374	3,388	2,419	-758	1,830	-3,510	-2,802	-2,958	-3,593	23	-458	1,133	4,044	3,301	4,439	3,397	2,811	1,991	2,044	743	-149	0	0	0
Net cash used in continuing operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-38,733	-36,954	-38,046	-38,802	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Loss from discontinued operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-17,739	-26,809	-26,106	-24,946	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Changes in operating assets and liabilities attributable to discontinued operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	276	-1,692	-1,712	-2,968	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in discontinued operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-13,466	-12,497	-11,774	-9,358	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in operating activities
-19,483	-17,643	-18,022	-28,367	-30,010	-30,422	-27,609	-15,839	-12,589	-10,989	15,818	6,005	-2,437	-11,850	-52,199	-49,451	-49,820	-48,160	-43,610	-45,265	-46,377	-42,869	-40,627	-37,495	-31,646	-28,929	-25,615	-21,797	-21,419	-20,973	0	0	0
Change in restricted cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	99	0	0	0	-	0	0	0
Cash paid for acquisition of Zuplenz rights
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-
Cash paid for acquisition of GALE-401
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,415	2,315	2,315	2,010	0	0	0	0	-	-	-	-
Purchase of short-term investments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Cash received in Apthera acquisition
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Maturities of short-term investments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Cash paid for purchase of equipment and furnishings
-	-	-	-	-	-	-	-	-	-	-	-	-	-	78	125	141	153	90	62	53	57	-186	-101	342	320	0	0	0	-	0	0	0
Net cash used in continuing investing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-78	-326	-342	-354	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Selling costs paid for sale of commercial assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash paid for commercial assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	534	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in discontinued investing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	10,233	10,233	10,199	10,749	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Disposal of equipment and furnishings
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Cash paid for lease deposit
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Cash transferred with the RXi spin-off
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Net cash used from investing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-85	10,155	9,907	9,857	10,395	-925	-3,752	-4,014	-5,528	-8,223	-4,428	-3,985	-12,040	-9,236	-9,956	-10,174	-87	0	0	0
Cash flows from financing activities:
Proceeds from issuance of Series A convertible preferred stock and common stock warrants, net of issuance costs
-	-	-	-	-	9,647	9,647	9,647	5,328	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of common stock, net of offering costs
21,959	15,971	0	0	0	-	-	-	-	-	-	-	-	-	31,804	20,189	25,484	47,416	58,120	58,120	52,825	10,704	0	0	0	-	-	-	-	36,378	0	0	0
Fair value of liability-classified warrants issued in connection with Series A convertible preferred stock recorded as issuance cost
-	-	-	-	-	-	-	-	-	-	-	-	-	-	9,866	5,590	5,590	10,296	0	0	0	-	-	-	-	-	-	-	-	7,286	0	0	0
Deemed dividend arising from beneficial conversion feature of Series A convertible preferred stock
-	-	-	-	-	-	-	-	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Repayment of interest and principal on long-term debt through issuance of common stock
-	-	-	-	-	3,721	3,587	3,701	1,631	0	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Collection of stock subscription receivable
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash paid for repurchase of warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	266	0	0	0
Cash paid for repurchase of common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Net proceeds from exercise of stock options
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	4,342	4,900	4,637	4,626	567	30	21	21	21	0	0	0
Proceeds from exercise of warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	10,717	17,712	17,770	18,372	7,815	856	954	4,526	5,708	0	0	0
Net proceeds from exercise of warrants
0	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from common stock issued in connection with ESPP
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-98	-170	-93	0	0	0
Proceeds from common stock issued in connection with Employee Stock Purchase Plan
-	-	-	-	-	-	-	-	-	-	-	-	-	-	95	277	277	309	309	282	320	263	0	0	0	-	-	-	-	-	-	-	-
Net proceeds from issuance of RXi convertible notes payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-500	0	0	0
Change in restricted cash related to debt principal paid in common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	1,500	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Principal payments on long-term debt
-	-	-	-	-	7,601	7,645	710	1,062	473	0	0	0	-	5,788	6,776	3,994	3,911	3,760	3,673	2,710	1,766	0	0	0	-	-	-	-	-	-	-	-
Principal payments on long-term debt
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Repayments of capital lease obligations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	0
Net cash provided by financing activities
23,639	19,569	17,174	31,237	20,614	23,123	23,079	8,826	10,273	5,534	-10,601	6,532	-2,751	16,500	31,746	13,855	21,812	43,845	54,700	55,134	50,824	24,260	22,101	60,166	70,577	55,949	70,824	33,444	40,373	42,434	0	0	0
Net decrease in cash, cash equivalents, restricted cash, and restricted cash equivalents
4,156	1,926	-848	2,870	-9,396	-7,299	7,628	5,145	9,842	6,703	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net increase in cash and cash equivalents
-	-	-	-	-	-	-	-	-	-	-	-	-	4,565	-10,298	-25,689	-18,151	6,080	10,165	6,117	433	-24,137	-26,749	18,243	34,946	14,980	35,973	1,691	8,780	21,374	0	0	0
Supplemental disclosure of cash flow information:
Cash received during the periods for interest
128	118	107	139	166	186	166	78	34	0	0	0	0	-	90	65	37	18	14	7	12	15	0	0	0	-	-	-	1	1	0	0	0
Cash paid during the year for interest
-	-	-	-	-	321	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash paid during the periods for interest
-	-	-	-	-	-	-	-	-	-	-	0	0	-	740	835	487	541	605	689	755	800	984	1,023	758	547	196	-16	0	1	0	0	0
Supplemental disclosure of non-cash investing and financing activities:
Debt issued in connection with warrant exchange agreements
-	-	-	-	-	966	966	966	888	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating right of use asset and current and non-current liability
672	549	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Reclassification of warrant liabilities upon exchange for shares of common stock
-	-	-	-	-	285	285	285	285	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Impact of anti-dilution protection on liability-classified warrants
70	243	243	734	664	491	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Offering expenses in accounts payable and accrued expenses and other current liabilities
0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net liabilities distributed to common stock holders in the RXi spin-off, net of cash transferred
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Fair value of shares mandatorily redeemable for cash upon exercise of warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Reclassification of warrant liabilities upon exercise
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	27,026	39,199	40,062	40,933	14,249	2,172	22,199	10,967	10,843	0	0	0
Stock issued
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Common stock issued in settlement of contingent purchase price consideration
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,579	0	0	0
Allocation of management expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Equipment and furnishings exchanged for common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Equipment and furnishings acquired through capital lease
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Non-cash lease deposit
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Value of restricted stock units and common stock issued in lieu of cash bonuses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Change in fair value of marketable securities before settlement
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,678	-4,229	-5,786	-9,709	-2,678	0	0	0
Issuance of common stock in settlement of GALE-401 milestone
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Fair value of shares issued to acquire Zuplenz rights
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-5,000	-5,000	0	0	0	0
Fair value of shares issued to acquire NeuVax
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0